Certain A Shares of Hubei Goto Biopharm Co.,Ltd. are subject to a Lock-Up Agreement Ending on 9-APR-2022.
April 08, 2022
Share
Certain A Shares of Hubei Goto Biopharm Co.,Ltd. are subject to a Lock-Up Agreement Ending on 9-APR-2022. These A Shares will be under lockup for 372 days starting from 2-APR-2021 to 9-APR-2022.
Details:
The controlling shareholder, actual controller, chairman and general manager of the company Xi Zubin, and the actual controller, deputy general manager and secretary of the board of directors Chen Wenjing promised within 36 months after the issuers shares are listed on the stock exchange, I shall not transfer or entrust others to manage the shares issued before the issuers IPO that I directly or indirectly hold, nor shall the issuer repurchase myself The shares issued before the issuers initial public offering, directly or indirectly. Institutional shareholding company controlled by the companys actual controller, deputy general manager, and secretary of the board of directors, Beijing Joint Innovation Investment Partnership (Limited Partnership), promised within 36 months after the issuers shares are listed on the stock exchange, I shall not transfer or entrust others to manage the shares issued before the issuers IPO that I directly or indirectly hold, nor shall the issuer repurchase myself The shares issued before the issuers initial public offering, directly or indirectly. Zhang Xin, a natural person shareholder of the company, promised within 36 months after the issuers shares are listed on the stock exchange, I shall not transfer or entrust others to manage the shares issued before the issuers IPO that I directly or indirectly hold, nor shall the issuer repurchase myself The shares issued before the issuers initial public offering, directly or indirectly.
Li Minglei, director and deputy general manager, Liu Xiangdong, director and chief financial officer, and Lu Fangxin, director of R&D, promised within 12 months after the issuers shares are listed on the stock exchange, I shall not transfer or entrust others to manage the shares issued before the issuers IPO that I directly or indirectly hold, nor shall the issuer repurchase myself The shares issued before the issuers initial public offering, directly or indirectly. Jiang Jianjun, the supervisor who holds the company's shares and all other shareholders of the Company promised within 12 months after the issuers shares are listed on the stock exchange, they will not transfer or entrust others to manage the shares issued before the issuers IPO that they directly or indirectly hold, nor shall the issuer repurchase myself The shares issued before the issuers initial public offering, directly or indirectly.
Hubei Goto Biopharm Co Ltd is a China-based company mainly engaged in the research and development, production and sales of steroidal drug raw materials. The Company's main products are starting materials and intermediates required for the production of steroid drugs. The starting materials refer to the products obtained from the conversion of plant sterols through biological fermentation technology. These products are important raw materials for downstream pharmaceutical intermediates and active pharmaceutical ingredient manufacturers and belong to the upstream products in the steroid drug industry chain. The Company's intermediate products mainly include sex hormone intermediates, progesterone intermediates, corticosteroid intermediates and other products.